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It has been recently demonstrated that activated Hageman factor is digested 
by plasmin to yield prealbumin fragments  (1)  which  convert prekallikrein to 
kallikrein, the enzyme that cleaves kininogen to yield bradykinin (2, 3). A rela- 
tion  between  this  kinin-forming system  and  the  complement  sequence  exists 
in terms of both the inhibitor of the first component of complement (CiINH), 1 
which inhibits both  the first component  (CI) ~ and kallikrein (4,  5),  as well as 
plasmin (6)  and the active Hageman factor (7), and the anaphylatoxin inacti- 
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grant from the John A. Hartford Foundation, Inc., and grant T-509 from the American Cancer 
Society, Inc. 
Recipient of a Faculty Research Award from the American Cancer Society, Inc. 
§ Recipient of a Special Fellowship  (5 FO3 AI42810-02) from  the National Institutes of 
Health. 
1 Abbreviations used in this paper: AAMe, N-acetyl-L-arginine  methyl ester hydrochloride; 
AGLMe, N-a-acetylglycyl-L-lysine  methyl ester acetate; ATMe, N-acetyl-L-tyrosine  methyl 
ester; TAMe, para-tosyl-L-arginine methyl ester hydrochloride;  CilNH, inhibitor of the first 
component  of complement;  DGVB ++, dextrose-Veronal-buffered  saline with Ca  ++ and Mg++; 
EA, sheep  erythrocytes coated  with  anti-sheep  hemolysin  made in  rabbits; GPC-EDTA, 
guinea pig sera diluted in EDTA; GVB ++, Veronal-buffered saline with Ca  ++ and Mg++; HAE, 
hereditary angioedema;  PTA, plasma thromboplastin antecedent; SBTI, soybean trypsin in- 
hibitor. 
2 The nomenclature  used conforms to that agreed upon by the World Health Organization 
(1968. Bull.  World [lealth Organ. 38:935.).  Sheep  erythrocytes (E),  sensitized  with rabbit 
antibody (A), react with the components of complement  (C) in the sequence C1, 4, 2, 3, 5, 6, 
7, 8, 9. The activated state of a component is signified by a bar above the component number. 
In addition to this convention,  the species of origin of the components is human unless indi- 
cated otherwise  by a superscript (guinea pig, gp). SAC1, SAC]4, and SAC]-~ refer to the 
proportion of hemolytically active sites formed per erythroeyte during  the interaction of EA 
with Ci, EAC1 with C4, and EAC~ with C2, respectively. 
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vator,  an  enzyme which  removes  the  C  terminal  arginine  residue  from  the 
C3a and C5a fragments of the third (C3) and fifth (C5) components of comple- 
ment  as well as from  bradykinin (8). Kallikrein not only cleaves the permea- 
bility factor bradykinin from kininogen but also is itself specifically chemotactic 
for human neutrophils (9), thus affording two of the essential ingredients of the 
inflammatory response. An additional function of the kinin-forming system iS 
to yield a fragment which profoundly alters the function of fully activated Ci. 
Fragment treatment of isolated, fully activated Ci, or partially activated CI, 
in whole human  serum markedly enhances  the hemolytic efficiency of Ci, in 
the latter instance without additional activation. Further, fragment-treated CI 
interacts  with  the  fourth  (C4)  and  the second  (C2)  components  of  comple- 
ment  to achieve a  much  greater inactivation of the  third  component  than  is 
accomplished by Ci, C4, and C2 in the absence of the fragment. 
Materials and Methods 
The sources and methods of handling of sheep erythrocytes, guinea pig sera, and human 
sera were as described  (10). Veronal-buffered saline, pH 7.5, ionic strength 0.145, containing 
0.1% gelatin, 0.00015 ~  Ca  ++,  and 0.0005 ~  Mg  ++  (GVB++),  dextrose-Veronal-buffered 
saline, ionic strength 0.075 (DGVB++), and 0.01 ~ or 0.04 M disodium ethylenediaminetetra- 
acetate (EDTA) were prepared as described  (11). The sources and methods of preparation of 
diethylaminoethyl- (DEAE-)  and  carboxymethyl-  (CM-)  cellulose,  Sephadex  G-200 and 
G-150 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.), hydroxylapatite, and the buffers 
used for chromatography have previously been reported (11-13). Para-tosyl-L-arginine  methyl 
ester hydrochloride (TAMe)  and N-acetyl-L-tyrosine methyl ester (ATMe)  were purchased 
from Mann Research Labs, Inc., New York; N-a-acetylglycyl-L-lysine methyl ester acetate 
(AGLMe)  and N-acetyl-L-arginine  methyl ester hydrochloride (AAMe) were obtained from 
Cyclo Chemical  Corp.,  Los Angeles, Calif. Soybean trypsin inhibitor (SBTI) was obtained 
from Worthington Biochemical Corp., Freehold, N. J. 
Preparation and Assay of Human Complement Components.--C1 was prepared from pooled 
human serum by low ionic strength precipitation at pH 7.5 (11, 14) with the addition of Ca  ++, 
0.00015 •;  further purification was achieved by Sephadex  G-200 gel filtration (12). The Ci 
preparation eluted with the 19S protein peak and it was found  to be fully activated (14). C4 
and C2 were prepared by DEAE- and CM-cellulose chromatography  (5,  11). C3  and  C5 
were isolated from DEAE-cellulose  chromatography (11) and further purified  by hydroxyl- 
apatite column  chromatography (15, 16). The sixth  (C6), seventh  (C7), eighth  (C8),  and 
ninth (C9) components of human complement were obtained from Cordis Corp., Miami, Fla. 
C1 gp and C2 gp were prepared as described  (11). 
Sheep erythrocytes were  coated with commercial  anti-sheep hemolysin  made in rabbits 
(EA). EAC1 gp cells were prepared by mixing EA in DGVB ++ with an equal volume of acti- 
vated first component  of guinea pig complement  (CigP), diluted to provide 250  effective 
•  "  3  o  molecules/cell in the fluid phase; after incubation at  0 C for 45 min, the cellular intermediate 
was washed three times in DGVB ++ and stored in the same buffer with penicillin and strep- 
tomycin (11). EAC4 were prepared from the EACi gp ceils (17) and further incubated in 0.01 M 
EDTA-GVB (18). EACI'-4  cells were prepared by exposing EACT~ cells to C1 gv (18). The pro- 
cedures for the effective molecule titrations of Ci  (19), CIINH (20), C4 (18), C2  (21), and 
C3  (22) were performed  as described. The number of Ci molecules bound to a cell (EAC1) 
was determined by Ci transfer (23). 1468  MODULATION OF  C1  ]?UNCTION.  I 
Purification and Assay of the Components of the Kinin-Forming System.--35 ml of serum 
were dialyzed overnight at  4°C  in 0.01 ~  phosphate buffer at pH  7.8,  and the precipitate 
formed was removed by centrifugation. The supernatant was applied to a 3.5 )( 30 cm DEAE- 
cellulose column equilibrated with 0.01 ~ phosphate buffer, pH 7.8, followed by washing with 
the equilibrating buffer and elution with a linear salt gradient to 0.3 za NaC1. The initial pro- 
tein peak  (OD  280  m~)  containing IgG, kallikrein,  and plasma thromboplastin antecedent 
(PTA) was concentrated by ultrafiltrafion using a UM-10 membrane (Amicon Corp., Lexing- 
ton, Mass.) to 5-10 ml,  and was then further concentrated by wall vacuum using collodion 
bags, number 100, (Schleicher & Schuell, Inc., Keene, N. H.) to a final volume of 2 ml. This 
material was applied to a 2.5  )<  150 cm Sephadex G-150 superfine column equilibrated with 
0.02 ~a tris (hydroxymethyl) aminomethane (Tris)  chloride pH 7.6. The pattern was developed 
by upward flow at 5 ml/hr and 2.5 ml fractions were collected. Heat-inactivated plasma pre- 
pared by heating fresh plasma at 61°C for 2 hr and dialyzing overnight against 0.15 ~t NaC1 
was used as a substrate for kallikrein (24). Kallikrein activity was determined by incubating 
between 0.05 and 0.2 ml of enzyme source with 0.2 ml of substrate for 2 rain at 37°C and meas- 
uring the bradykinin generated by adding the mixture to the organ bath containiug the guinea 
pig ileum used for bioassay. Control tubes containing the enzyme source or the substrate were 
evaluated separately for bradykinin generation. The kallikrein peak was pooled, concentrated, 
and its purity assessed by disc gel electrophoresis at pH 9.3  (Buchler Instruments, Inc., Fort 
Lee, N. J.)  (25) and by electro-focusing in 4% polyacrylamide gels (26). In each instance a 
single broad band was obtained representing a mixture of kallikrein, IgG, and trace contami- 
nation with PTA. 
The shortening of the partial thromboplastin time of PTA-deficient plasma was used to 
assay for PTA. 0.05 ~  ml of PTA source was incubated for 2 rain at 37°C with 0.05 ml cepha- 
lin (6 mg/ml) and 0.05 ml PTA-deficient plasma in siliconized glass tubes. 0.05 ml 0.05 ~ CaCI2 
was added, and the clotting time determined at room temperature. The tubes were tilted each 
minute and the end point defined as the time required for the clot to adhere to the glass tube. 
P[asmin was measured  by  digestion of azocasein as  described by  Hummel  et  aI.  (27). 
Kininogen was prepared as previously described by Spragg et al.  (3). 
For the esterolytic assay of kallikrein,  each synthetic substrate was dissolved in 0.08  M 
phosphate buffer, pH 7.8, ionic strength 0.14. Esterolytic activity was measured by a modifi- 
cation of the colorimetric method described by Siegelman et al.  (28). 0.2 ml of enzyme was 
incubated with 0.8 ml of substrate in phosphate buffer at a concentration of 10 mmoles/ml. 
At 1 min and 31 min at 37°C, 0.4 ml of enzyme-substrate mixtures were removed and trans- 
ferred to small tubes containing 0.25 ml of 15% trichloroacetic acid (TCA), and the precipitate 
formed was removed by centrifugation. 0.05  ml of 2% potassium permanganate (KMnO4), 
0.05 ml of 10% sodium sulfite (Na2SO3), and 2 ml of chromotropic acid were added in sequence 
to 0.25  ml of supernatants, followed  by incubation in a  boiling  water bath for t5 min. The 
purple color developed by the interaction of the methanol, derived from the splitting of the 
ester substrates with chromotropic acid, was measured in the spectrophotometer at 580 m~. 
The values were compared with those of a standard curve of methanol and the results calcu- 
lated as millimoles per liter of methanol liberated in each reaction mixture during the 30 min 
incubation at 37°C. 
RESULTS 
Enhancement  of the C]  Hemolytic  Activity  by Fractions with Kinin-Generating 
Capacity 
Aliquots of 0.5 ml of C1 containing 1000 units/ml were incubated with 0.1  ml DGVB  ++ 
or 0.1 ml of five individual pools of fractions eluted from a DEAE-cellulose column during the IRMA  GIGLI,  ALLEN  P.  KAPLAN,  AND  K.  ~'RANK AUSTEN  1469 
purification of the enzyme kallikrein. Control samples of 0.5 ml DGVB  ++ received 0.1 ml of 
each of the pools.  The mixtures were incubated at 30°C  for 30  rain and the Ci hemolytic 
activity of each sample measured. 
Five areas capable of generating bradykinin with fresh plasma were observed 
as previously described (29) (Fig.  1). The first peak, eluted with the starting 
buffer,  contains IgG globulin,  PTA, and releases bradykinin from either fresh 
plasma, heat-inactivated plasma, or purified kininogen  (29) and therefore con- 
tains kallikrein  activity. The second peak contains activated Hageman factor, 
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FIG. 1.  DEAE-cellulose chromatography of human sera with assessment of protein con- 
centration (O),  kinin generation from fresh plasma  (O),  and C1  enhancement (---). The 
salt gradient used for elution of the column is expressed as the corresponding  molarity of NaC1. 
of progressively smaller  size  and  net negative charge  (29).  Plasminogen  and 
plasmin  overlap  peaks  two  and  three.  Enhancement  of  the  Ci  hemolytic 
activity was observed with the first and fourth peaks, while peaks two, three, 
and five were negative in this regard.  Ci was precipitated in the step which 
preceded chromatography  of the  supernatant  and  no  CI  hemolytic activity 
was demonstrable in any of the five kinin-generating  peaks. 
The  Ci  enhancement  produced by the kallikrein-rich  peak  1 was further 
analyzed in terms of its dose response effect. 
Aliquots of 0.5 ml of Ci containing 1000 units/ml were incubated with DGVB  ++ or seven 
increasing amounts (0.01M).I ml) of peak 1. The final volume of a]l the mixtures was brought 
to 0.6 ml. A control sample of 0.5 ml DGVB  ++ received 0.1 ml of peak 1. The mixtures were 
incubated at 30°C for 30 rain and the C1 hemolytic activity measured in each sample. 1470  MODULATION OF  ci  FUNCTION. I 
As shown  in  Fig.  2,  the  Ci  activity increased from  1000  units/ml in  the 
control sample to 2500 units/ml with increasing amounts of peak 1, at which 
point a plateau of Ci enhancement was reached. The kallikrein peak incubated 
with buffer alone was free of CI hemolytic activity. 
Five 0.5 mI samples of Ci diluted to contain 1000 units/ml received different  additions 
during a total incubation time of 40 rain. The respective additions were 0.01 ml of a concen- 
trated peak 1, 0.01 ml SBTI 0.1 mg/ml, peak 1 followed by SBTI for 30 rain, SBTI followed 
by peak 1 for 10 min, or buffer. In a sixth sample 0.01 ml peak 1 and  0.01 ml SBTI were 
incubated for 10 rain before receiving 0.5 ml C1. The final volume of all samples was brought 
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FIG. 2.  Enhancement of Ci hemolytic activity by incubation with different  amounts of 
peak 1 (Fig. 1)  (O) as compared with buffer  (O). 
The results are depicted in Fig. 3. SBTI did not influence the Ci hemolytic 
activity alone (B). Peak 1 increased the Ci hemolytic activity 300 %  (C); the 
increase was limited to 125 % when peak 1 was previously incubated with SBTI 
(D). The SBTI has a  lesser effect when its preincubation with kallikrein was 
omitted (E), and has virtually no effect when added after the interaction of CI 
with  peak  1  (F).  This  suggests  that  the  enhancement  was  due  to  a  SBTI- 
sensitive proteolytic enzyme such as kallikrein. 
Accordingly, in  a  separate  experiment  the  dose  response  of  the  effect  of 
SBTI on TAMe hydrolysis, and kinin formation as well as CI  enhancement, 
was examined. 
Five duplicate samples of SBTI containing  10, 1, 0.1, 0.01, and 0.001 mg/ml in saline were 
incubated with an equal volume of buffer or peak 1. A control sample of peak 1 received buffer 
alone. After I0 rain at 30°C the samples were analyzed. IRMA  GIGLI~  ALLEN  1  ~.  KAPLAN,  AND  K.  FRANK  AUSTEN  1471 
Inhibition of kinin generation was slightly more sensitive to SBTI than the 
splitting  of the synthetic substrate;  50%  inhibition  was achieved with  0.0050 
mg and 0.0075 mg of SBTI respectively. In contrast almost 100 times as much 
SBTI (0.5 rag)  was required  to achieve 50%  suppression of CI enhancement, 
suggesting that the enhancing activity may reside in a structure other than the 
active  enzymatic site  of a  TAMe  esterase  such  as kallikrein.  Attention  was 
therefore focused on the possibility that  the  CI-enhancing material in peak 1 
was somehow related to the more negatively charged material observed in peak 
4  (rig.  1). 
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Fio. 3.  Inhibition  by SBTI of the Ci enhancement produced by peak 1. CI incubated 
with DGVB  ++ (A), Ci incubated with SBTI (]3), CI incubated with peak 1 (C), peak 1 in- 
cubated with SBTI before the addition of C1 (D), Ci incubated with SBTI before the addi- 
tion of peak 1 (E), and C1 incubated with peak 1 before the addition of SBTI (F). 
Recognition  of a C1-Enhaneing Material Apparently Derived from the 
Kallikrein-Containing Fraction 
Peak  1 of the DEAE-cellulose  column was subjected  to Sephadex G-150 gel filtration. 
The fractions were combined into eight pools, concentrated  by pressure dialysis to a final 
volume of 10 ml, and tested for kilfin formation on heated plasma and for CI enhancement by 
their effect on C[, 1000 units/ml. 
As shown in Fig. 4,  a  protein  peak produced largely by IgG was found in 
fractions  120-160;  superimposed  on  the  descending  portion  of this  peak was 
bradykinin-generating  activity,  attributable  entirely  to kallikrein  at  approxi- 
mately 45 %  of the column bed volume. A  peak of CI-enhancing activity was 
observed in the same position. A  second peak of CI enhancement was present 
at  approximately  80%  bed volume.  This  material  designated  Kf was  devoid 1472  MODULATION  OF  C1  ];UNCTION.  I 
of  kinin-generating  activity  from  either  fresh  or  heat-inactivated  plasma, 
indicating that neither kallikrein nor the active Hageman factor fragments was 
present.  Rechromatography of the material corresponding to 45 %  of the bed 
volume again yielded Ci-enhancing activity at 45 and 80 % bed volume, with 
the same characteristics as observed in the initial  chromatogram. 
In order to determine whether or not Kf  represents some portion of the Ci 
molecule, it  was examined for the esterolytic and proteolytic characteristics of 
Ci. The ability of Kf to hydrolyze synthetic substrates  was studied in an ex- 
periment in which 0.2  ml samples of Kf were incubated with 0.8 ml of TAMe, 
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FIG. 4.  Gel filtration on Sephadex G-150 of peak 1 (Fig. 1) with assessment of protein 
concentration (•), kinin generation from fresh plasma (©), C1 enhancement (---), and par- 
tial thromboplastin time (PTT) (--). 
ATMe,  AAMe,  and  AGLMe  containing  10  mmoles  of  substrate/ml. 
Kf  did  not  hydrolyze any  of  the  synthetic substrates  studied.  The  capacity 
of Kf to destroy C4 and C2 in  the fluid phase was determined by incubating 
0.1  ml  samples  of Kf with 0.5 ml of  C4 containing 1000 units/ml,  or C2 con- 
taining 100 units/ml, or with buffer. After 30  rain at 30°C the residual C4 and 
C2 were measured in each sample. 90 and 30% of C4 and  C2 respectively were 
destroyed by Ci  while  Kf  failed  to  inactivate  these  two  components in  the 
fluid phase. 
The heat stability of Kf at 56°C was evaluated in terms of Ci enhancement. 
When plotted  logarithmically there was a  linear  loss  of activity with  a  half- 
life of 35 rain. The pH stability of Kf was examined in a range of 4-9 by adding 
0.1  M  HC1 or 0.1 M NaOH to the Tris chloride buffer. After 1 hr  the  pH  in IRMA  GIGLI,  ALLEN  P.  KAPLAN,  AND  K.  :FRANK AUSTEN  1473 
each  sample  was  brought  to  7.5  and  the  final  volume adjusted  to  1  ml  with 
buffer.  At  pH's  4,  5,  and  6  there  was  a  20%  loss  in  Ci-enhancing  capacity, 
while there was no loss between pH  7 and 9. 
Effect of Kf on Cell-Bound Functions of C1 
Utilization of C2 by EAC14 and EAC1Kf4.-- 
Two 0.5 ml samples of C[ containing 1800 units/ml were incubated with 0.1 ml of either 
buffer or Kf. A  control sample of Kf received 0.5  ml buffer.  After 30  rain at 30°C,  the C1 
hemolytic activity was measured in all samples.  C1 incubated with buffer contained 1800 Ci 
units, that incubated with Kf exhibited 4300 units, and Kf alone was devoid of any hemolytic 
activity. These three samples were diluted to the same final dilution (1:18). Two aliquots of 
EACZt cells 1 X  10S/ml were incubated with an equal volume of the diluted C1 and the third 
aliquot of cells with C1Kf. After 15 min at 30°C,  the samples were centrifuged and washed 
in DGVB ++.  One of the EACI'4 preparations  and  the EAC1Kf4 intermediate were resus- 
pended in buffer,  while the other EAC 14 was resuspended in the diluted Kf. All samples were 
incubated 15 min at 30°C, centrifuged, washed once in buffer,  and resuspended to the original 
cell concentration.  10 ml of each cellular intermediate prewarmed at 30°C received 10 ml of 
C2, 1.2 units/ml, and the incubation was continued. 1 ml samples were removed at time inter- 
vals up to 15 rain, added to 1.5 ml of guinea pig sera diluted 1:22.5 in 0.04 M EDTA (GPC- 
EDTA), and the reaction developed for 60 rain at 37°C. 
The  results  (Fig.  5)  show  that  the  EACI'-4  generated  with  untreated  Ci 
followed by treatment  with buffer or Kf had a  Tm~ of 4.5 min with a  maximal 
hemolytic activity (Zm~)  with  C2  of 0.85  and 0.95  SAC142 respectively, while 
EAC1Kf4  had a  Tm~ of 3  rain and a  Zm~ of 1.98 SAC1Kf42. The results were 
similar  in  a  subsequent  experiment  even  when  the  CiKf  was  diluted  more 
than  the Ci so as to achieve a  comparable number  of Ci hemolytic units,  that 
is Kf shifted  the Tm~x from 3.5 rain  to  1.75  rain and the Zm~x from 0.85  to  1.59 
sites. 
Interaclion of C1 and C1Kf with EA C712.  - 
An EAC42 intermediate was generated to provide cells with bound unactivated C2. EACZt 
cells,  1 X  109/ml, in DGVB  ++ at pH 8.5, with a final Mg  ++ concentration of 0.001 M, were 
incubated with an equal volume of C2 diluted in the same buffer to contain less  than  1 C2 
unit when tested with routinely prepared EAC14 cells. The mixture was incubated at 30°C 
for 30 min, centrifuged at room temperature, washed once, and resuspended in the same buffer 
to the original volume. The buffers used for washing  and resuspension were prewarmed  at 
30°C. Activation of these EAC42 cells was obtained by incubating these cells with aliquots of 
Ci or C1Kf described above diluted to contain 5, 20, and 50 C1 units/ml. 9 ml of C1 and C1Kf 
dilutions were prewarmed at 30°C,  and each received 1 ml of EAC42 cells,  1  X  109/ml. A 
sample of EAC42 was incubated with Kf without C1.  Upon mixing and at time intervals up 
to 20 rain, 1 ml samples were removed and added to 1.5 ml of GPC-EDTA. The reaction was 
developed at 37°C for 60 min. 
Fig. 6  shows that untreated  Ci produced 0.42, 0.57, and 0.65 SAC142 with a 
Tm~ of  7, 3,  and  2.75  rain respectively with  the three  Ci  concentrations  used, 1474  MODULATION OF  ci  FUNCTION. I 
while CiKf at the same concentrations formed  1.35,  1.5,  and  1.6  SAC1Kf42, 
with a  Tm,x of 3.25,  1.75,  and  1.75  rnin respectively. Thus for the same input 
of hemolytic units, CIKf generated cells with a shorter Tm~ and a higher Zm~, 
than  untreated  Ci,  even  when  the unactivated  C2  was  already bound  to the 
cell. 
E~ecl of Kf on C1 Binding.- 
Two aliquots of C[ and CiKf were diluted in either DGVB ++ or GVB  ++ to contain 20 
units of C[ each. 9 ml of these four C1 preparations, prewarmed  at 30°C, received  1 ml of 
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~'FIo. 5.~ T,n~  of  cells generated with Ci  and  EAC7~ (EACI-4, O),  the  same  EAC]4 
treated with Kf (O), and cells generated with CiKf and EAC4 (EAC1Kf4, A). Z refers to 
the number of hemolytically  active sites generated by each cellular intermediate during the 16 
min of incubation with C2. 
EAC42 cells, 1 X  109. The mixtures continued  to be incubated at 30°C, and at time intervals 
up to 20 min 1 ml samples were rernoved and added to 1.5 ml of GPC-EDTA. 
The results, Fig. 7,  show that in DGVB~+  Ci formed 0.58  SACI-~, with a 
Tm~ of 3.5 rain; 0.85  SACI-~ were measured in GVB  ++ with a  T,  .... of 5 rain. 
In contrast CIKf in DGVB  ++ generated 1.7 SAC1Kf42 with a  Tm~  of 1.5  rain, 
but only 1.1  SAC1Kf42 in GVB  -H- with a  T,x,~ of 3.5 rain, suggesting that the 
effect of Kf was not  to create a  form of Ci  capable of moving about the cell. IRMA  GIGLI~ ALLEN P.  KAPLAN~ AND  K.  FRANK AUSTEN  1475 
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FIo. 6.  Tm~x  developed by EACT~2 cells treated with three concentrations of Ci  (O  =  5, 
[]  =  20,  /%  =  50 units/m])  and  CiKf (O  =  5,•  =  20,•  =  50units/ml).Zrefers  to 
the number of hemolytically active sites generated. 
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FIG.  7.  Kinetics of EAC14--2 and  EAC1Kf42 formation by EACT~2 and  Ci or CiKf in 
DGVB  ++  (EAC]-~, •; EAC1Kf42,  0) or GVB  ++ (EACh'2, N; EAC1Kf42, O). 
This  point  was  further  investigated  in  an  experiment  in  which  cell-bound  CI 
and  CIKf  were compared  after washing the cells. 
Two samples of Ci treated  either with buffer or Kf were serially diluted in DGVB  ++, 
1/2000-1/32,000. Duplicate 0.5 ml samples of Ci or CiKf received 0.5 ml of EAC7~ to generate 1476  MODULATION  OF  C]  FUNCTION.  I 
EAC14. After 30 min at 30°C, one series of EAC14 and EAC1Kf4 samples was centrifuged, 
washed once in DGVB  -~+, and resuspended in 1 ml DGVB++; the duplicate series of samples 
was kept unwashed  The reaction mixtures were developed with (;2 and GPC-EDTA. 
The results indicated that CiKf generated significantly more hemolytically 
active sites  (12,800  units/roll  than  Ci  (1820  units/roll and  that  these  sites 
tolerated washing (8450 units/roll at least as well as those generated without 
Kf (845 units/roll. 
Attention was next directed to the capacity of the effect of Kf to be trans- 
ferred. 
C1  and  C1Kf containing  3850 and 20,0(t0 units/ml respectively were both diluted  in 
DGVB  ++ to contain 20 units/ml. Aliquots of each sample were incubated with an equal vol- 
ume of EA, 1 X  10S/ml. After 30 rain at 30°C and 15 min at 0°C, both reaction mixtures 
were centrifuged, and the C1 present in both supernatants  measured. The cells were resus- 
pended to their original volume in DGVB  ++ and the number of C1 molecules bound to the 
EA determined  by transfer of Ci from dilutions of the EAC1 and EAC1Kf in GVB  ++ to 
EAC4 cells, 1 X l0  s. In addition, dissociation of C1 or CiKf at low ionic strength was also 
measured by transfer. 
The results show that of  the 20 Ci  units/ml added to the EA, 5 units were 
found in the supernatant and  14 units on the cells as  assessed by transfer in 
GVB  ÷+. In contrast with Kf-treated Ci only 0.6 units were found in the super- 
natant and  10  units by  transfer.  Although only half of  the  CiKf input was 
recovered, the hemolytic activity observed must represent enhanced Ci mole- 
cules  since  the  initial dilution of  CIKf  was  five  times  greater  than  that  of 
the  starting C1;  if enhancement had disappeared during the  transfer only 4 
Ci  hemolytic units would have been expected. The undetected activity could 
have either been lost because of disappearance of the Kf effect, or not have been 
susceptible to transfer because of persistent binding to the donor cell. Neither 
Ci nor CIKf transferred well in DGVB  ++, 
Ejfect of Kf on C1 Activation.-- 
Two 2 ml aliquots of C1 prepared as previously described (14) and C1 each containing 
1000 units/ml were incubated with 0.1 ml Kf or buffer. At 0 time and 5 rain intervals up to 
60 min 0.01 ml samples were removed and diluted 1 : 1000 in DGVB  ++. 0.5 ml samples of each 
dilution were immediately added to 0.5 ml EACJ,2 cells, 1 X 10S/ml. The samples were incu- 
bated for 15 min at 30°(; and developed with GPC-EDTA. C[ incubated with buffer produced 
the formation of 0.32 SACI4~ at 0 time and 0.45 SACI-~ at the end of 60 min incubation; 
incubation with Kf increased the hemolytic activity to 0.75 SAC1Kf42 at 0 time and 1.02 
SAC1Kf42 at 60 min. 
C1  incubated either with  buffer or Kf failed to  prepare  the  EAC42  inter- 
mediate for  lysis. The lack of  effect of Kf on C1  indicated that its action is 
restricted to already activated Ci molecules. IRMA  GIGLI,  ALLEN  P.  KAPLAN,  AND  K.  FRANK  AUSTEN  1477 
C3 Utilization by C3 Convertase Generated by C1 and C1Kf.-- 
Two batches of EAC4 ceils were converted to EAC1-4 and EAC1Kf4 by incubation with 
either C1 or CiKf diluted to contain 15 units/ml. The cells were washed and resuspended in 
DGVB ++. 0,5 ml aliquots of C3 diluted to contain 50 units/ml were incubated with 0.5 ml 
of the intermediate 1  X  108/rul or with buffer. All samples received 0.5  ml C2  containing 
100 units/ml. After 30 rain at 30°C  the cells were sedimented and the C3 in the supernatant 
fluid was measured. 
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FIG. 8.  C3 utilization by EAC142  (O) and EAC1Kf42  (O) as compared with incubation 
in buffer ([]). The titrations for residual C3 are shown on  the left, while the right depicts 
the per cent of C3 utilization. 
in  the  supernatant  after  incubation  with  EAC142  cells,  and  only  22  were 
detected in the sample incubated with the EAC1Kf42  intermediate. 
Effect of Kf on Fluid Phase Functions of C-] 
Fluid l~hase Destruction of C4 by C1 and CTKf.-- 
Two aliquots of C1 were incubated either with buffer or Kf and a sample of Kf was incu- 
bated with buffer alone. Untreated Ci containing 400 units/mI and Kf-treated CI exhibiting 
1900 units/ml were diluted to contain 50 units/ml. Four aliquots of a  single dilution of C4 
containing 1300 units/ml were incubated with either buffer, Kf, C1, or C1Kf. After 30 rain 
at 30°C the residual C4 was measured in each reaction mixture. 1478  MODULATION OF C1  FUNCTION.  I 
Of the 1300 units present in the samples incubated with buffer or Kf at the 
end of the experiment (Fig. 9), 600 units were destroyed by CI, while only 50 
were destroyed by the same number of Ci hemolytic units present in the CiKf 
sample. 
Fluid Phase Destruction of C2 by CIKf in the Presence and Absence of C4.-- 
Samples of C1  and  C1Kf were diluted to contain 100 units/ml each. Four duplicate 0.5 
ml samples of C2 containing 20 units/ml were incubated with 0.5 ml of either buffer,  Kf, C1, 
or CIKf. One sample of each mixture received 0.5  ml C4,  100 units/ml,  the other, 0.5  ml 
buffer.  After 30 min at 30°C, the residual C2 in each sample was measured. 
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FIG. 9.  C4 destruction by C1 and C1Kf. 
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Residual C4 in samples incubated with bufferw 
11 units were  destroyed by CI, while CIKf inactivated 3  C2 units. Of the 
18 units detected in the mixture of C2 and C4, 16 were destroyed when CI was 
added and only 3 when CiKf was present (Fig. 10). Kf alone did not have an 
effect on either C4 or C2 alone or in combination. 
Effect of Kf on Human Sera 
In order to examine the effect of Kf on C1  and  CI  which has not been sub- 
jected  to  chromatographic  separation,  studies  were  carried  out  in  normal 
human  sera  and in serum from a  patient  with hereditary  angioedema  (HAE), 
deficient in the CIINH. 
Two 0.5 ml samples of serum from a patient with HAE, diluted  1:200 in DGVB  ++, were 
incubated with 0.1 ml Kf or 0.1 ml buffer.  After 30 min at 30°C the C1 activity was measured IRMA  GIGLI,  ALLEN  P.  KAPLAN,  AND  K.  FRANK  AUSTEN  1479 
in dilutions  of both samples. The C1 titer in the sample incubated with buffer was 146,000, 
while incubation with Kf enhanced the C1 activity to 212,000 units/ml. 
Although  this  experiment  clearly  showed  that  Kf  acted  upon  C1  in  whole 
serum, it failed  to demonstrate whether  this  effect involved  activation  of  C1, 
or was  only because  of  an  effect  on  the  already  activated  CI  molecules,  and 
thus this point was further examined. 
Normal human serum and HAE serum were diluted 1 : 100 in DGVB  ++. Two 2 ml samples 
of both diluted sera were incubated at 30°C; one sample of each received 0.1  ml Kf, and the 
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FIG. 10.  C2 destruction by Ci and CiKf in the absence and presence of C4. Residual C2 
in samples incubated with buffer,  Ci, CiKf, C4, C4 and Ci, and with C4 and C1Kf. 
and diluted  1:1000  in DGVB ++. 0.5 ml of each dilution was immediately added to 0.5  ml 
EAC42  cells 1  )<  l0 s prepared as previously described.  The mixtures were incubated for 5 
rain at 30°C and the reaction developed by the addition of GPC-EDTA. The results are shown 
in Fig.  11. HAE  serum incubated  with buffer produced  the formation  of 0.7  SAC142 at 0 
time of incubation and 0.6 SAC142 at the end of 60 min. 
Incubation  of HAE  serum with Kf produced  0.94  SAC1Kf42  at 0  time and 
1.50  at  the end of 60 rain. Normal human  serum incubated  either with buffer 
or  Kf  failed  to  generate  lyric  intermediates  during  the  5  rain  incubation  of 
diluted  serum  with  EAC42.  The  kinetic  data  are  most  consistent  with  the 
enhancing  effect  of  Kf  being  limited  to  active  Ci  molecules present  in  HAE 
sera. 1480  MODULATION  OF  C1  FUNCTION.  I 
DISCUSSION 
Several years ago a material associated with a partially purified preparation 
of  human  kallikrein  (30)  was  recognized  as  being  capable  of  enhancing  the 
hemolytic activity of fully activated first  component of human complement. 
In  the  present  studies  chromatography of human  serum  to yield  the  active 
enzymes of the kinin-forming sequence again revealed an association between 
the kallikrein-containing  fraction and  Ci  enhancement  (Fig.  1).  Peak 1 con- 
taining  kallikrein  also contains  IgG and  PTA  (1,  31).  PTA can be partially 
1.5 
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FIG. 11.  Effect  of Kf on human sera. Normal human serum (D, m) and I-IAE serum 
(©,  e) were incubated either with buffer (D, O) or Kf (it,  e). 
separated from kallikrein  and  the  Ci-enhancing  material by Sephadex G-150 
gel  filtration  (Fig.  4).  The  kallikrein-rich  fraction  enhances  Ci  hemolytic 
activity in a dose response fashion (Fig. 2) and its effect is reversed by pretreat- 
ment of the kallikrein with SBTI (Fig. 3). The concentration of SBTI required 
to prevent CI enhancement is 100 times greater than that necessary to suppress 
kinin generation or esterase activity; it may well be that the enhancement of 
C] activity by the kallikrein-rich peak 1 is not directly due to interaction with 
the active enzymatic site of kallikrein.  SBTI does not inhibit  PTA  (32). 
It is noteworthy that the DEAE-cellulose chromatography of serum (Fig. 1) 
revealed a second region of Ci-enhancing activity in an area known to contain 
partially  digested  Hageman  factor  fragments but  not  kallikrein  (1,  29).  In IRMA  GIGLI,  ALLEN  P.  KAPLAN~  AND  K.  F1LA.NK AUSTEN  1481 
addition further chromatography and rechromatography of the kallikrein-rich 
material by Sephadex gel filtration revealed a continual shift of Ci-enhancing 
capacity to material  of a  molecular weight  considerably less  than kallikrein 
(Fig. 4), designated Kf. Kf was distinguished from the Hageman factor frag- 
ments by its failure to generate bradykinin from fresh plasma, and from kalli- 
krein by its inability to produce bradykinin from heat-inactivated plasma. The 
lack  of activity against  such  synthetic amino  acid  esters as  AAMe,  TAMe, 
AGLMe, or ATMe not only further distinguishes Kf from kallikrein but also 
from the subunits of CI,  Cir,  and CIs  (33). It is differentiated from Clq on 
the basis of gel filtration and chromatographic characteristics (34). 
The enhancement of CI  function by Kf could be because of activation of 
unrecognized precursor molecules, reactivation of active molecules which have 
somehow decayed, or an increased efficiency of already active Ci  molecules. 
There is no evidence that Kf will activate isolated precursor C1 or C1 in normal 
serum or serum from a patient with HAE devoid of CIINH (Fig. 11). An effect 
of Kf to reduce the binding of Ci could create an apparent increase in efficiency 
b__y permitting the molecule to move about the cell so as to create multiple active 
42  sites; however in contrast to Ci,  CiKf demonstrated a  reduction of Tmax 
and Zm~ upon interaction with EAC42 cells in GVB  ++ (Fig.  7). Further, the 
EAC1Kf4 intermediate tolerated washing in a  manner similar to the EAC14 
intermediate.  CiKf tolerated transfer and there was again no evidence of in- 
creased dissociability. 
The effect of Kf on Ci was demonstrable only when the interaction occurred 
in the fluid phase before interaction with the cellular intermediate. When CIKf 
was interacted with an EAC4 cell, and the reaction was brought to completion 
by the addition of C2 and the terminal components, the Tm~ was shorter and 
the Zm~ greater than when  Ci  was  used  either at a  comparable dilution  of 
starting CI (Fig. 5) or in terms of the same number of apparent hemolytic units. 
When Ci and CiKf of comparable hemolytic activity were examined for their 
capacity to activate a site on the EACTI2 intermediate, C1Kf again yielded a 
shorter Tin= and a greater Zm,~ than was achieved by the introduction of Ci 
(Fig. 6). The capacity of C1Kf to yield a greater Znl~ and a shorter Tr,~ than 
CI  even when  employed at  a  greater  dilution  so  as  to  contain  comparable 
hemolytic activity in a CI titration suggests that the effect of Kf is to yield a 
more efficient molecule and not reactivate molecules which have somehow lost 
their activity, unless such reactivated molecules are more efficient than those 
still in the starting state. 
That Kf does indeed lead to a functionally altered form of Ci is supported 
by finding that fluid phase C4 and  C2  are spared from inactivation  (Figs.  9 
and  10).  If  failure  to  rapidly  inactivate is  synonymous with  more  efficient 
utilization of C4 and C2, then the capacity of C1-Kf to activate cell-bound 742 
(Fig. 6)  to give a shorter Tm~ and a greater Z .... than Ci would be expected. 1482  :MODULATION  OF  ci  FUNCTION.  I 
Similarly  the  EAC1Kf4  intermediate  would utilize fluid  phase  C2  to give  a 
shorter Tm,x and Zm~x than the EAC14 intermediate as was observed (Fig. 5). 
The view that C1Kf permits a more efficient utilization of C4 and C2 so as to 
generate  more 42  sites  as  recognized  by  a  shorter  Tm~x and  a  greater Zm~ 
(Fig. 5 and 6) would be consistent with the finding of increased C3 inactivation 
by an EAC1Kf42 cell (Fig. 8). 
SUMMARY 
An activity designated Kf can be separated from human serum and shown 
to give a  100-300%  enhancement in the hemolytic activity of fully activated, 
fractionated C~I. The enhancement of Ci  activity is not because of activation 
of precursor  C1  and it is not attributable to an effect on Ci binding.  EAC42 
or EAC4 intermediates interacted with CIKf exhibit a greater T~x and shorter 
Zm~x than  when  such  intermediates  are  reacted  with  the  same  number  of 
hemolytic units of C1. C3 consumption by the EAC1Kf42 intermediate greatly 
exceeds that of the EAC14---2 intermediate produced from the same EACYi cells 
by comparable inputs  of  the  other  two  complement components.  Taken  to- 
gether, these findings suggest that Kf-treated CI achieves more efficient utiliza- 
tion of C4 and C2 to create a larger number of 42 sites as appreciated on the 
intermediates by shorter  Tm,x and a  greater Z~x,  and an increased  capacity 
to utilize C3. The capacity of Kf to enhance Ci upon introduction into whole 
serum of a patient with hereditary angioedema (HAE) in a manner comparable 
to its effect on fractionated CI suggests that the effect of Kf may be pertinent 
to certain pathophysiologic conditions of man. 
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